Diadem Reports New Data Showing Its AlzoSure^® Predict Blood Test Can Accurately Identify “Rapid Progressors” Who Will Develop Alzheimer’s Disease Within Two Years

by Claire | Jan 9, 2023 | Uncategorized

At CTAD 2022 Diadem Highlights How Its AlzoSure^® Predict Prognostic Blood Test for Alzheimer’s Disease Will Help Patients and Facilitate Development of New Therapies

by Claire | Dec 5, 2022 | Uncategorized

Diadem Builds Out Executive Team As It Prepares for Commercialization of Its AlzoSure^® Predict Prognostic Test for Alzheimer’s Disease

by Claire | Nov 21, 2022 | Uncategorized

Diadem Builds Out Executive Team As It Prepares for Commercialization of Its AlzoSure® Predict Prognostic Test for Alzheimer’s Disease —Diadem to Participate in the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference— Milan, Italy, November 21, 2022 – Diadem...

Diadem Names Clinical Diagnostics Industry Veteran Paul Kinnon as CEO

by Claire | Oct 23, 2022 | Uncategorized

DIADEM NAMES CLINICAL DIAGNOSTICS INDUSTRY VETERAN PAUL KINNON AS CEO —Kinnon Joins to Lead Development and Commercialization of First Minimally Invasive Blood-Based Prognostic Test for Early Alzheimer’s Disease—   —Accessible Early Diagnosis Will Transform...

Development of Blood-Based Alzheimer’s Prognostic Propels Diadem to Finalist Status for Both the Gaetano Marzotto Company Prize and 2030 Social Impact Special Prize

by Claire | Oct 23, 2022 | Uncategorized

DEVELOPMENT OF BLOOD-BASED ALZHEIMER’S PROGNOSTIC PROPELS DIADEM TO FINALIST STATUS FOR BOTH THE GAETANO MARZOTTO COMPANY PRIZE AND 2030 SOCIAL IMPACT SPECIAL PRIZE —Prestigious Awards Celebrate Entrepreneurial Company Innovation and Pioneering New Products Supporting...